Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma

Serena De Luca, Rosa Fonti, Luigi Camera, Barbara Salvatore, Antongiulio Faggiano, A. Ciarmiello, Sabrina Segreto, Annamaria Colao, Marco Salvatore, Silvana Del Vecchio

Research output: Contribution to journalArticle

Abstract

Objective: The aim of our study was to determine the role of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) and indium-111 Octreotide single photon emission tomography (111In-Octreotide SPECT) in the evaluation of metastatic medullary thyroid carcinoma (MMTC). Methods: Twenty-five MMTC patients were retrospectively evaluated. All patients had undergone whole-body 18F-FDG-PET/CT including 20 who had also undergone 111In-Octreotide SPECT within a maximum interval of 6 weeks. Diagnostic contrast-enhanced computed tomography (CT) alone or as part of 18F-FDG-PET/CT examination was performed in all patients. Results: Contrast-enhanced CT detected a total of 131 lesions including 79 enlarged lymph nodes and 14 bone lesions. 18F-FDG-PET/CT visualized a total of 92 true positive lesions (SUVmax range 1.1–10.0, mean 4.0 ± 1.7) including 66 lymph nodes, 7 of which were not enlarged on CT, and 8 bone metastases. In the 20 patients studied with both techniques, a total of 64 and 46 true positive lesions were detected by 18F-FDG-PET/CT and 111In-Octreotide SPECT, respectively. In particular, 18F-FDG uptake was found in 43 lymph nodes and in 7 bone metastases whereas 111In-Octreotide uptake was detected in 27 lymph nodes and in 10 bone metastases. Conclusions: In MMTC patients, 18F-FDG-PET/CT provides a useful contribution mainly in evaluating lymph node involvement whereas 111In-Octreotide SPECT can contribute to the detection and somatostatin receptor characterization especially of bone lesions.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalAnnals of Nuclear Medicine
DOIs
Publication statusAccepted/In press - Jan 11 2016

Keywords

  • In-Octreotide SPECT
  • F-FDG-PET/CT
  • Contrast-enhanced CT
  • Medullary thyroid carcinoma
  • Multimodal imaging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Multimodal imaging with <sup>18</sup>F-FDG-PET/CT and <sup>111</sup>In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma'. Together they form a unique fingerprint.

  • Cite this

    De Luca, S., Fonti, R., Camera, L., Salvatore, B., Faggiano, A., Ciarmiello, A., Segreto, S., Colao, A., Salvatore, M., & Del Vecchio, S. (Accepted/In press). Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma. Annals of Nuclear Medicine, 1-8. https://doi.org/10.1007/s12149-015-1056-5